In an interview for Medical Alley's "For the Record," the founder and CTO of Francis Medical, Michael Hoey, shares why he sought a more compassionate approach for treating prostate cancer and how he discovered water vapor technology. He also gives a window into how things are progressing at Francis Medical...
September 30, 2020: CCX Media visited Francis Medical to interview President and CEO Mike Kujak, and get an inside look at how Francis Medical is thriving and moving forward during the COVID-19 pandemic. This two-minute video includes recent news about a $4M investment by Coloplast.
September 29, 2020: Francis Medical Adds Urology Company Coloplast to Its Roster of Investors. The $4 million equity investment will support the company in optimizing its product design and executing a pivotal U.S. study.
This video demonstrates how water vapor therapy will provide a revolutionary new prostate cancer treatment that is tough on prostate cancer yet gentle on patients.
June 17, 2020: CCX Media visited Francis Medical for exclusive interviews with CEO and President, Mike Kujak, and Founder and CTO, Michael Hoey. Their two-minute video includes an explanation of our revolutionary water vapor therapy, as well as plans for the future, including our VAPOR 1 clinical study.
Press Release: Francis Medical Announces First Patient Enrolled in VAPOR 1 IDE Study for Water Vapor Ablation of Prostate Cancer
June 9, 2020: Francis Medical, Inc. announces the enrollment of their first patient in the company’s VAPOR 1 clinical study, an early feasibility study evaluating the safety and efficacy of the company’s minimally invasive water vapor ablation therapy for the treatment of prostate cancer.
On the heels of successful patient treatments in Panama City, Panama, Francis Medical is overcoming challenges brought on by the COVID-19 pandemic to bring their ground-breaking water vapor technology to men dealing with prostate cancer.
October 16, 2019: Dr. Jonathan Jarow joins Francis Medical, Inc. as the company’s chief medical officer (CMO) to lead Francis Medical’s clinical and regulatory efforts, including the VAPOR trials evaluating water vapor ablation as a minimally invasive treatment for prostate cancer.
December 17, 2018: Francis Medical, Inc. has been featured in BioWorld MedTech, a leading news source of advances in medical technology.
December 13, 2018: Francis Medical announces the completion of a $18.0 million round of Series A funding. Arboretum Ventures led the Series A with co-investments from H2Oey Ventures (an affiliate of Solas BioVentures Fund), Tonkawa, and Boston Scientific. Francis Medical plans to use this capital to further develop the company's cancer ablation therapy.